Research Frontier

Active Frontiers

1. Disease-Agnostic Editing

Status: Rapid progress | Key work: Prime editing suppressor tRNAs (Liu, Nature Nov 2025)

Suppressor tRNAs installed via prime editing can read through premature stop codons, addressing approximately 30% of rare genetic diseases with a single molecular strategy. Error rates improved from 1-in-7 to 1-in-101 at normal stop codons. This shifts gene therapy from per-disease approaches to a platform model. 19 base/prime editing clinical trials underway across 5 countries.

What to watch: Clinical trial results for suppressor tRNA therapies; regulatory pathway for disease-agnostic platform approvals.

2. Epigenetic Editing (No-Cut Gene Activation)

Status: Early stage | Key work: UNSW Sydney / St Jude (Jan 2026)

Gene reactivation via demethylation without DNA breaks. Applied to Sickle Cell Disease (fetal hemoglobin reactivation). Eliminates double-strand break risks (cancer pathway disruption, chromosomal rearrangements). Potentially reversible via re-methylation. Currently at cell study stage — animal trials planned.

What to watch: Animal model results; durability of demethylation in vivo; head-to-head comparison with Casgevy (approved CRISPR therapy for Sickle Cell).

3. One-Time Cardiovascular Treatments

Status: Active (Phase 1 complete) | Key work: Cleveland Clinic ANGPTL3 trial (Nov 2025)

Single CRISPR infusion (CTX310) targeting ANGPTL3 via lipid nanoparticles achieved LDL -50% and triglycerides -55% in 15 patients, sustained 60+ days, no serious adverse events. Targets the world's leading cause of death with a one-time treatment instead of lifelong medication.

What to watch: Phase 2/3 trial design; durability beyond 60 days; pricing and reimbursement models for one-time cardiovascular gene therapies.

4. AI-Accelerated Gene Therapy

Status: Active | Key work: CRISPR-GPT (Stanford, Sep 2025)

LLM copilot trained on 11 years of expert discussions automates experimental design, off-target prediction, and risk assessment. Novice undergraduate achieved first-attempt gene editing success. Compresses development timelines from years to months.

What to watch: Integration with automated wet lab robotics; biosecurity implications of democratized gene editing; application to clinical trial design optimization.

Knowledge Gaps

Areas where our current sources provide insufficient coverage:

• Base editing clinical data — We have context on prime editing trials but limited data on how base editing clinical trials are performing (outcomes, safety, dosing).
• Non-liver delivery methods — Our sources focus on LNP liver delivery and ex vivo approaches. Emerging delivery vectors for brain, muscle, lung (engineered AAV, antibody-conjugated LNPs) are underrepresented.
• Longevity and aging applications — Gene editing for aging-related targets (telomere biology, senescence, epigenetic reprogramming) is not covered in current sources.
• CRISPR for cancer — CAR-T and other CRISPR-based immuno-oncology approaches are absent from our current source set.
• Regulatory pathways — How regulators (FDA, EMA) are adapting frameworks for one-time gene therapies, disease-agnostic platforms, and AI-designed experiments.
• Gene editing economics — Manufacturing costs, pricing models, insurance coverage for therapies costing $1-3M per patient.